Free Trial

Enliven Therapeutics (ELVN) News Today

Enliven Therapeutics logo
$15.99 -0.41 (-2.50%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$16.81 +0.82 (+5.12%)
As of 05/27/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELVN Latest News

Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Buy" by Analysts
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been given an average rating of "Buy" by the five ratings firms that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust Corp
Northern Trust Corp raised its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 331,500 shares of the company's stock af
Enliven Therapeutics, Inc. stock logo
Soleus Capital Management L.P. Has $1.70 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Soleus Capital Management L.P. trimmed its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 68.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 75,405 shares of the company's
Enliven Therapeutics, Inc. stock logo
HC Wainwright Issues Pessimistic Outlook for ELVN Earnings
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Enliven Therapeutics in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst R. Burns now expects that the company will earn
What is HC Wainwright's Estimate for ELVN Q1 Earnings?
Enliven Therapeutics, Inc. stock logo
Polar Capital Holdings Plc Acquires 1,739,668 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Polar Capital Holdings Plc lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 267.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,389,668 shares of the company's
Enliven Therapeutics, Inc. stock logo
Janus Henderson Group PLC Purchases 290,153 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Janus Henderson Group PLC grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 27.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,331,877 shares of the company's stock after acquiring an additional 290,153 shares during the peri
Enliven Therapeutics, Inc. stock logo
Patient Square Capital LP Increases Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Patient Square Capital LP grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 147.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 224,038 shares of the company's stock after buying an additional 133,466 shares during the period. Enl
Enliven Therapeutics, Inc. stock logo
Nicholas Investment Partners LP Sells 16,110 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Nicholas Investment Partners LP lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 157,635 shares of the company's stock after selling 16,110 shares during the period. Ni
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics (ELVN) to Release Quarterly Earnings on Tuesday
Enliven Therapeutics (NASDAQ:ELVN) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-enliven-therapeutics-inc-stock/)
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Decreased by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC cut its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 39.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,710 shares of the company's stock after s
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by 5AM Venture Management LLC
5AM Venture Management LLC lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,629,765 shares of the company's stock after selling 122,409 shares during t
Enliven Therapeutics, Inc. stock logo
Acuta Capital Partners LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Acuta Capital Partners LLC lowered its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 267,368 shares of the company's stock after selling 29,00
Enliven Therapeutics, Inc. stock logo
Boxer Capital Management LLC Acquires New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 671,358 shares of the company's sto
Enliven Therapeutics, Inc. stock logo
RA Capital Management L.P. Sells 212,247 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)
RA Capital Management L.P. reduced its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 848,986 shares of the company's stock afte
Enliven Therapeutics, Inc. stock logo
Marshall Wace LLP Sells 96,624 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Marshall Wace LLP reduced its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 70.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,382 shares of the company's stock after selling 96,6
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Boothbay Fund Management LLC
Boothbay Fund Management LLC lowered its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 21.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,890 shares of the company's stock after selli
Enliven Therapeutics, Inc. stock logo
Lord Abbett & CO. LLC Raises Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Lord Abbett & CO. LLC lifted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 386,211 shares of the company's stock after purchasi
Enliven Therapeutics, Inc. stock logo
Artia Global Partners LP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Artia Global Partners LP acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 102,900 shares of the company
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Adage Capital Partners GP L.L.C.
Adage Capital Partners GP L.L.C. reduced its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 18.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 650,000 shares of the compa
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics (NASDAQ:ELVN) Trading 10.8% Higher - Should You Buy?
Enliven Therapeutics (NASDAQ:ELVN) Trading 10.8% Higher - Here's What Happened
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 5,000 Shares
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 5,000 shares of the firm's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $16.42, for a total transaction of $82,100.00. Following the completion of the sale, the chief executive officer now owns 985,392 shares in the company, valued at $16,180,136.64. This represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Enliven Therapeutics: Awaiting Additional Trial Data
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Fmr LLC
Fmr LLC raised its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,495,871 shares of the company's stock after acquiring an additional 199,692 sh
Enliven Therapeutics, Inc. stock logo
Federated Hermes Inc. Takes $2.65 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Federated Hermes Inc. acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 117,552 shares of the company's stock, valu
Enliven Therapeutics, Inc. stock logo
Vanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Vanguard Group Inc. raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,975,655 shares of the co
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low - Time to Sell?
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year Low - Should You Sell?
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - Here's What Happened
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - What's Next?
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase - Should You Buy?
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Should You Buy?
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% Following Insider Selling
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider Selling
Enliven Therapeutics, Inc. stock logo
Pictet Asset Management Holding SA Has $21.88 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 972,293 shares of the company's stock after
Enliven Therapeutics, Inc. stock logo
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at $490,590. This represents a 12.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,500.00 in Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $22.50, for a total value of $22,500.00. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $517,500. The trade was a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Enliven Therapeutics, Inc. stock logo
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Here's What Happened
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Should You Sell?
Enliven Therapeutics, Inc. stock logo
16,322 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Purchased by Intech Investment Management LLC
Intech Investment Management LLC purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,322 shares of the company's stock, valued at approxima
Enliven Therapeutics, Inc. stock logo
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company's stock, valued at approximately $20,665,399.68. This represents a 1.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.

ELVN Media Mentions By Week

ELVN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ELVN
News Sentiment

0.34

1.03

Average
Medical
News Sentiment

ELVN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ELVN Articles
This Week

8

3

ELVN Articles
Average Week

Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners